Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Infectious diseases of the nervous system: pathogenesis and worldwide impact

Open Access Oral presentation

HIV and antiretroviral therapy in the brain: neuronal injury and repair

Ronald Ellis*, Dianne Langford, Eliezer Masliah, Igor Grant, Robert Heaton, Joseph Wong, Davey Smith, Scott Letendre and Allen McCutchan

Author affiliations

Department of neurosciences, University of California, San Diego, CA, USA

For all author emails, please log on.

Citation and License

BMC Proceedings 2008, 2(Suppl 1):S13  doi:


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/2/S1/S13


Published:23 September 2008

© 2008 Ellis et al; licensee BioMed Central Ltd.

Oral presentation

Worldwide over 30 million people are infected with human immunodeficiency virus (HIV-1). Although HIV is both neurotropic and neurovirulent, the spectrum of HIV-associated neurocognitive disorders (HAND) remains under-recognized. Combination antiretroviral therapy has improved the health of millions of those living with HIV, yet antiretroviral drugs show highly variable and often inadequate penetration into the CNS. As a result, patients' quality of life continues to be diminished by milder, residual neurocognitive impairments that have not been effectively addressed. HIV causes synaptodendritic neuronal injury that can be measured post-mortem and is a likely source of neurocognitive decline. By carefully selecting specific antiretrovirals and supplementing them with neuroprotective agents, physicians might be able to facilitate innate CNS repair, promoting enhanced synaptodendritic plasticity, neural function and clinical neurological status.